Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04157465
Other study ID # PGI/IEC/2019/001924
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 7, 2019
Est. completion date June 30, 2024

Study information

Verified date April 2022
Source Postgraduate Institute of Medical Education and Research
Contact Nipun Verma, MD, DM
Phone +919914208562
Email nipun29j@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Early treatment of invasive fungal infections (IFI) may prevent undue mortality in acute on chronic liver failure (ACLF) patients. We aim to study the impact of early empiric treatment (based on clinical suspicion) of IFI as compared to pre-emptive treatment (based on biomarkers and culture positivity) on the outcomes in ACLF patients with suspected IFI in a randomized trial. The ACLF patients with clinically suspected IFI would be randomly allocated to empiric treatment or pre-emptive treatment group and followed up clinically to assess the impact on survival, clinical outcomes and cost-effectiveness and safety of such an approach. The protocol is designed to cut- down unnecessary usage and to curtail the duration of antifungals use in ICUs based on biomarkers/culture-driven stoppage rules. The results will fuel further studies on formal cost-effective analysis and antimicrobial stewardship protocols in ACLF patients.


Description:

Research question: Does an early empiric antifungal therapy improve 28-day overall survival as compared to pre-emptive antifungal therapy in critically ill, non-neutropenic adult ACLF patients with suspected IFI? This study will be a single-center prospective randomized open-label with blinded end-point PROBE assessment and conducted at Liver ICU. ACLF patients aged 18 to 75 years with all three criteria will be included 1. ICU stay of 48 hours or recent hospitalization 2. Two or more risk factors for IFI 3. Clinical suspicion of IFI Exclusion criteria A Neutrophil count of less than 500 per mm3 B Recent antifungal treatment in the past 1months C Hepatocellular carcinoma or other active malignancy D Known hypersensitivity or contraindication to Liposomal AmB E HIV positivity or on HAART F Pregnancy or lactation G Moribund patients Eligible patients will be randomly assigned, in a 1:1 ratio to receive either early empiric systemic antifungal therapy (SAT: based on risk factors and clinical suspicion) or Pre-emptive SAT (based on risk factors, clinical suspicion and radiological/investigation based evidence of fungal infection) in addition to standard medical therapy SMT and followed up for a period of 28-days or transplant or death Empirical therapy will be Liposomal AmB 3 to 5 mg per kg of body weight per day. It is preferred because of maximum efficacy, widest spectrum, and safety in liver disease Pre-emptive therapy with liposomal AmB will be given if the treatment initiation rules are met including fungal biomarkers positivity, Mycological or radiological evidence of IFI Proven-IFI will be treated as per IDSA or ESCMID guidelines in either group Stoppage rules in both groups will be based on fungal biomarkers and cultures that will be done twice weekly and twice negative bio-markers or fungal cultures at day7 and 10 will be essential to stop treatment In case of intolerable adverse effects or contraindications to LipoAmB, the patients will undergo treatment as per IDSA guidelines Standard Medical Therapy will be as indicated and will include nutritional support, rifaximin lactulose albumin diuretics proton-pump inhibitors multivitamins and antibiotics Outcomes will include survival at 28-day, clinical outcomes, cost-effectiveness and safety of two approaches of antifungal therapy


Recruitment information / eligibility

Status Recruiting
Enrollment 216
Est. completion date June 30, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria (All three must be present): 1. ICU stay >48 hours or admission in a tertiary care hospital prior to the current admission 2. Two or more risk factors for IFI from amongst the following:- 1. Mechanically ventilated at least = 48 hours 2. Treatment with broad-spectrum antibacterial agents for more than 3 days 3. Arterial or central vein catheter = 2days 4. Diabetes Mellitus 5. Total parenteral nutrition = 48 hours 6. Acute renal failure requiring any form of renal replacement therapy =48hours 7. Pancreatitis related hospitalization > 7days in last 3 months 8. Steroid use, immunosuppressant use in the preceding 30 days 9. High disease score as defined as MELD=20 or APACHE II =16 10. Refractory ascites, norfloxacin prophylaxis 11. Gastrointestinal tract surgery, abdominal perforation or anastomotic leaks or any invasive procedures or surgeries in the last 7days 12. Chronic pulmonary diseases including COPD or Tuberculosis 13. Moderate to severe sarcopenia as defined by The Royal Free Hospital-global assessment (RFH-GA) scale60 (As per Appendix "4" ) 14. Firm diagnosis of H1N1 influenza infection in the last 3 months 3. Clinical suspicion of IFI as defined by any of the following: 1. Evidence of unresolved sepsis/SIRS(= 2/4) despite appropriate broad-spectrum antibiotics beyond 3days 2. Recrudescence of fever after a period of defervescence of at least 48 hours while still on antibiotics and without other apparent cause 3. Tracheobronchial ulcer, nodule, plaque or pseudo-membrane 4. Sino-nasal infection: features of acute sinusitis with at least 1 of acute localized pain, nasal ulcer, eschar, orbital involvement or 5. Respiratory symptoms: - Worsening respiratory insufficiency despite appropriate ventilator support and antibiotics - Any 2 of Pleuritic chest pain, pleural rub, dyspnea, hemoptysis 6. Characteristic skin lesions suspected of fungal infection 7. Unexplained worsening of encephalopathy after initial improvement Exclusion Criteria: 1. Neutrophil count of less than 500/mm3 2. Current or recent antifungal treatment in the past 1 months 3. Hepatocellular carcinoma or other active malignancy 4. Known hypersensitivity or contraindication to Liposomal AmB or any other AmB preparation 5. Human immunodeficiency virus seropositivity on rapid card test/ELISA, or currently on combination antiretroviral therapy (cART) 6. Pregnancy as confirmed by urine pregnancy test or lactation 7. Moribund patients as defined as 1. = 4 organ failure as per CLIF-SOFA score 2. Signs of brainstem death- absent brainstem reflexes 3. Expected ICU stay <48 hours

Study Design


Intervention

Other:
Treatment strategy trial
Participants will be randomly allocated in a 1:1 ratio after meeting eligibility criteria to either early empiric or pre-emptive strategy of treatment with antifungals. The antifungal treatment initiation will be at the time of allocation in the empiric group. The treatment initiation rules in the pre-emptive group will include Fungal Biomarkers positivity (Beta-D Glucan>150 pg/ml, Galactomannan index>1.0) Mycological evidence of fungal infection on fungal cultures from a non-sterile site Radiological evidence of fungal infection Other Investigations suggestive of fungal infection viz. endophthalmitis, vegetations suspicious of fungal infection, Vegetations on echocardiography with negative blood cultures for bacteria that is non-responsive to appropriate antibiotics, refractory culture-negative spontaneous bacterial peritonitis Treatment duration will be guided by serum biomarkers (BDG and GM) and fungal cultures.

Locations

Country Name City State
India Postgraduate Institute of Medical education and Research Chandigarh UT

Sponsors (1)

Lead Sponsor Collaborator
Postgraduate Institute of Medical Education and Research

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Other Number of participants with adverse events due to antifungals requiring cessation of therapy Number of participants out of whole group who would develop adverse events due to antifungals that will require cessation of therapy within 28 day of enrollment 28 day
Other Out of pocket expenditure Out of pocket expenditure incurred by the patients in two groups 28 day
Primary Overall Survival 28-day overall survival 28 day
Secondary Incidence of proven or probable IFI Incidence of proven or probable IFI at 28 days 28 day
Secondary In-hospital mortality Number of participants dying in hospital due to any cause within 28 day of enrollment 28 day
Secondary Evolution of organ failures as assessed by chronic liver failure-sequential organ failure score (CLIF-SOFA) Development of new or worsening organ failures as defined by chronic liver failure -sequential organ failure (CLIF-SOFA) scores within 28 days of enrollment. CLIF-SOFA score ranges from 0-24 incorporating 6 organ systems and 0 being best and 24 being worst. 28 day
Secondary Evolution of serum 1, 3 Beta-D Glucan (BDG; in pg/ml) levels throughout the study period Trends of 1, 3 Beta-D Glucan (BDG) throughout the study period that will be done on twice weekly intervals after enrollment 28 day
Secondary Evolution of serum Galactomannan index (GM; in %) throughout the study period Trends of Galactomannan index (GM; in %) throughout the study period that will be done on twice weekly intervals after enrollment 28 day
Secondary Incidence of key events like new onset ventilator associated pneumonia, urinary tract infection, spontaneous fungal peritonitis Incidence of key events like new onset VAP, UTI, fungal SBP 28 day
Secondary Mechanical ventilation free days Duration free from mechanical ventilation within 28 days of enrollment 28 day
Secondary Length of ICU and hospital stay Effect on length of ICU, hospital stay within 28 day of enrollment 28 day
Secondary Treatment success rate Treatment success rate, successful treatment being defined as
Survival beyond 7 days of start of SAT with resolution of sepsis attributable to IFI
Absence of new/ breakthrough IFI during treatment or within 7 days of completion
Absence of treatment discontinuation related to toxicity/lack of efficacy
28 day
See also
  Status Clinical Trial Phase
Recruiting NCT05985863 - Human Umbilical Cord Mesenchymal Stem Cell Transplantation for The Treatment of Acute-on-Chronic Liver Failure Phase 1/Phase 2
Not yet recruiting NCT04822922 - Safety of UC-MSC Transfusion for ACLF Patients Phase 2
Recruiting NCT04578301 - Predicting Acute-on-Chronic Liver Failure After Surgical Intervention in Chronic Liver Disease
Completed NCT04983108 - Utility of Liver and Splenic Stiffness in Predicting Esophageal Varices in Patients With Acute on Chronic Liver Failure
Withdrawn NCT05940610 - The Safety and Efficacy of MSC-EVs in Acute/Acute-on-Chronic Liver Failure Phase 1/Phase 2
Not yet recruiting NCT05036031 - Transplantation for EASL-CLIF and APASL ACLF Patients: a Retrospective Cohort Study
Recruiting NCT05019352 - Cytokine Adsorption in Acute-on-chronic Liver Failure N/A
Recruiting NCT05421351 - Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF
Completed NCT02321371 - Effect of Goal Directed Ammonia Lowering Therapy in Acute on Chronic Liver Failure Patients With Hepatic Encephalopathy. N/A
Not yet recruiting NCT06069037 - SALT for Treatment of Patients With Early ACLF N/A
Completed NCT02965560 - Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure
Recruiting NCT03713489 - Platelet Transfusion in HBV-related acute-on Chronic Liver Failure N/A
Withdrawn NCT03629015 - Safety Study of Stemchymal® in Acute Liver Failure Phase 1
Recruiting NCT04621812 - Role of Fecal Microbiota in Predicting Graft Rejection and Sepsis Among Recipients of Living Donor Liver Transplant in First Year.
Suspended NCT03737448 - TRimetazidine for acUte on Chronic Liver Failure STudy Phase 1
Recruiting NCT06128421 - Individual Nutrition Support in HBV-ACLF Patients at Nutrition Risk N/A
Recruiting NCT05700708 - Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Completed NCT04238416 - Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF Phase 1
Completed NCT03456518 - Pattern of Acute on Chronic Liver Failure in Patient With HCV Related Chronic Liver Disease
Recruiting NCT03987893 - PEG3350 in ACLF With Hepatic Encephalopathy Phase 4